undamentalytics Newsletter
Sign in

Parabilis Medicines, Inc. (PBLS) stock

Add to watchlist

Add holding +

NASDAQ: PBLS Nasdaq Biotechnology Next results ~November 12, 2026

Parabilis Medicines, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling14 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds76 adding, 0 cuttingOf 28 active managers that changed their stake, 28 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 773% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Parabilis Medicines, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Short interest rising. Shares sold short rose 52% in a month to 7.6% of tradable shares.

Latest results

Earnings per share
-$2.12 against an average estimate of -$0.24: missed by 772.9%
Share reaction
-0.9% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.38

Parabilis Medicines' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.8%
  • 1 week+8.9%
  • 1 month-10.0%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Leadership
  4. Results
  5. Insider trade
  6. Insider trade
  7. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Parabilis Medicines, Inc. valuation models and calculator

No model value for Parabilis Medicines, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $500000 and EPS of −$0.38 (range −$0.45 to −$0.25) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.58 — $1m —
Next −$2.19 +15% $5m +300%

How the EPS forecast has moved

In the last 30 days, 0 analysts raised Parabilis Medicines, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Parabilis Medicines, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 30 days ago 7 days ago Now Current fiscal year, 30 days ago: −$1.66 Current fiscal year, 7 days ago: −$1.66 Current fiscal year, Now: −$2.58 −$2.58 Next fiscal year, 30 days ago: −$1.90 Next fiscal year, 7 days ago: −$1.90 Next fiscal year, Now: −$2.19 −$2.19

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
30 days ago −$1.66−$1.90
7 days ago −$1.66−$1.90
Now −$2.58−$2.19

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.24 −$2.12 −772.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202666
  2. Sep 202655
  3. Aug 202655

Counts of recommendations published by analysts covering Parabilis Medicines, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.6%
of tradable shares
Days to cover
7.03
at average volume
Short interest, 1 month
+52%
to October 15, 2026
Held by institutions
82%
of shares
Held by insiders
7.0%
of shares
Employees
145
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
−16.7%
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
0 up, 1 down
typical move ±0.9%
After a week
1 up, 0 down
typical move ±5.8%
After a month
0 up, 1 down
typical move ±3.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −0.9% +0.5% +5.8% −3.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$2.7B
Institutions reporting
78
Positions opened / closed
76 / 0

Top buyers and sellers, Q2 2026: 76 institutions bought and 0 sold ; the biggest buyer was RA Capital Management, L.P (+28.9M shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $792M 28.9M 29.2% —
FMR LLC $282M 10.3M 10.4% —
Arch Venture Management, LLC $176M 6.4M 6.5% —
Venbio Partners LLC $144M 5.3M 5.3% —
Alphabet Inc. $135M 4.9M 5.0% —
Nextech Invest Ltd. $128M 4.7M 4.7% —
Cormorant Asset Management, LP $126M 4.6M 4.7% —
Regeneron Pharmaceuticals, Inc. $114M 4.2M 4.2% —
Siren, L.L.C. $81.9M 3.0M 3.0% —
Farallon Capital Management, L.L.C. $64.8M 2.4M 2.4% —
Jupiter Topco LLC $62.7M 2.3M 2.3% —
Frazier Life Sciences Management, L.P. $52.6M 1.9M 1.9% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Parabilis Medicines, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $441M 14 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $441M net buying
Insider Date Trade Shares Price Value
Ra Capital Management, L.P. Director July 22, 2026 Buy 47,250 $29.77 $1.4M
Ra Capital Management, L.P. Director July 21, 2026 Buy 37,723 $30.00 $1.1M
Ra Capital Management, L.P. Director July 21, 2026 Buy 6,504 $29.17 $189,722
Ra Capital Management, L.P. Director July 21, 2026 Buy 21,696 $27.96 $606,620
Ra Capital Management, L.P. Director July 20, 2026 Buy 98,433 $27.13 $2.7M
Ra Capital Management, L.P. Director July 20, 2026 Buy 32,987 $27.72 $914,400
Sebulsky Alan Director June 15, 2026 Buy 5,000 $26.00 $130,000
Sebulsky Alan Director June 15, 2026 Buy 4,065 $27.10 $110,162
Sebulsky Alan Director June 12, 2026 Buy 8,435 $27.67 $233,396
Sebulsky Alan Director June 11, 2026 Buy 12,500 $20.00 $250,000
Ra Capital Nexus Fund Iii, L.P. Director June 11, 2026 Buy 1,460,397 $20.00 $29.2M
Ra Capital Nexus Fund Iii, L.P. Director June 11, 2026 Buy 19,728,353 $20.00 $395M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 13, 2026

Recent SEC filings

Data status

When each part of this page on Parabilis Medicines, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Parabilis Medicines, Inc. in brief

What does Parabilis Medicines, Inc. do?
Parabilis Medicines, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Parabilis Medicines, Inc.'s stock ticker?
Parabilis Medicines, Inc. trades under the ticker PBLS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Parabilis Medicines, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., FMR LLC and Arch Venture Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Parabilis Medicines, Inc. stock?
Over the last 12 months, Parabilis Medicines, Inc.'s directors and officers reported 14 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Parabilis Medicines, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Parabilis Medicines, Inc. announces its own schedule.